Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Manufacturer end adefovir development

    Project Inform Perspective
    |May 29, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Gilead Sciences halted adefovir development for HIV treatment due to FDA concerns. The drug faced rejection over safety issues, with potential side effects outweighing benefits.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010

    Area of Science:

    • Antiviral drug development
    • HIV/AIDS therapeutics
    • Pharmaceutical regulatory affairs

    Background:

    • Gilead Sciences investigated adefovir as a potential treatment for Human Immunodeficiency Virus (HIV) infection.
    • The U.S. Food and Drug Administration (FDA) reviewed the existing data for adefovir's efficacy and safety.
    • An advisory committee to the FDA recommended against the drug's approval.

    Discussion:

    • The FDA indicated that current data was insufficient for adefovir approval.
    • Concerns were raised regarding serious potential side effects associated with adefovir.
    • The benefit-risk profile of adefovir was deemed unfavorable by the advisory committee.

    Key Insights:

    • Development of adefovir for HIV has been discontinued by Gilead Sciences.

    Related Experiment Videos

  • FDA's decision was based on insufficient data and significant safety concerns.
  • The Antiviral Drugs Advisory Committee's recommendation heavily influenced the regulatory outcome.

    • Outlook:

    • Gilead Sciences may need to conduct further studies to potentially gain FDA reconsideration.
    • The discontinuation highlights the rigorous safety and efficacy standards for HIV medications.
    • Future development of adefovir for other indications, if any, remains uncertain.